

CORRECTION

# Correction: The sorafenib anti-relapse effect after alloHSCT is associated with heightened alloreactivity and accumulation of CD8+PD-1+ (CD279+) lymphocytes in marrow

Andrzej Lange, Emilia Jaskula, Janusz Lange, Grzegorz Dworacki, Dorota Nowak, Aleksandra Simiczjew, Monika Mordak-Domagala, Mariola Sedzimirska

The following information is missing from the Funding section: Publication of this study was supported by Wroclaw Centre of Biotechnology, programme The Leading National Research Centre (KNOW) for years 2014–2018.

## Reference

1. Lange A, Jaskula E, Lange J, Dworacki G, Nowak D, Simiczjew A, et al. (2018) The sorafenib anti-relapse effect after alloHSCT is associated with heightened alloreactivity and accumulation of CD8+PD-1+ (CD279+) lymphocytes in marrow. PLoS ONE 13(1): e0190525. <https://doi.org/10.1371/journal.pone.0190525> PMID: 29304116



## OPEN ACCESS

**Citation:** Lange A, Jaskula E, Lange J, Dworacki G, Nowak D, Simiczjew A, et al. (2018) Correction: The sorafenib anti-relapse effect after alloHSCT is associated with heightened alloreactivity and accumulation of CD8+PD-1+ (CD279+) lymphocytes in marrow. PLoS ONE 13(12): e0209108. <https://doi.org/10.1371/journal.pone.0209108>

**Published:** December 6, 2018

**Copyright:** © 2018 Lange et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.